CYP2D6 genotype in psychiatric patients:: Impact on haloperidol metabolism.

被引：0

作者：

Schmider, J ^{[1
]}

Sachse, C ^{[1
]}

Walter, S ^{[1
]}

Filler, D ^{[1
]}

Kaiser, R ^{[1
]}

Roots, I ^{[1
]}

Brockmöller, J ^{[1
]}

机构：

[1] Humboldt Univ, Univ Clin Charite, Inst Clin Pharmacol, Berlin, Germany

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 1998年 / 63卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PII51

引用

页码：185 / 185

页数：1

共 50 条

[41] CYP2D6 genotype and tamoxifen response [J].

Rae, JM ;

Goetz, MP ;

Hayes, DF ;

Ingle, JN ;

Li, L ;

Storniolo, AM ;

Stearns, V ;

Flockhart, DA .

BREAST CANCER RESEARCH, 2005, 7 (05)

[42] CYP2D6 genotype and tardive dyskinesia [J].

Sajjad, SHA .

BRITISH JOURNAL OF PSYCHIATRY, 1997, 170 :580-580

[43] CONCORDANCE OF PHENOTYPE AND GENOTYPE FOR CYP2D6 [J].

MCLEOD, HL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (04) :463-463

[44] The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients [J].

Yokono, A ;

Morita, S ;

Someya, T ;

Hirokane, G ;

Okawa, M ;

Shimoda, K .

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (06) :549-555

[45] CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms [J].

Simic, Iveta ;

Potocnjak, Ines ;

Kraljickovic, Iva ;

Benic, Mirjana Stanic ;

Cegec, Ivana ;

Nahal, Danica Juricic ;

Ganoci, Lana ;

Bozina, Nada .

PHARMACOGENOMICS, 2016, 17 (13) :1385-1389

[46] The effect of CYP2D6 and CYP2C19 genotypes on the metabolism of amitriptyline in Japanese psychiatric patients [J].

Hirokane, G ;

Morita, S ;

Yokono, A ;

Someya, T ;

Takahashi, S ;

Okawa, M ;

Shimoda, K .

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 :S7-S8

[47] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM [J].

Nahid, N. ;

Kanumuri, S. ;

Sharma, A. ;

Wang, D. ;

Johnson, J. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 :S74-S75

[48] RELATIONSHIP BETWEEN CYP2D6 GENOTYPE AND HALOPERIDOL PHARMACOKINETICS AND EXTRAPYRAMIDAL SYMPTOMS IN HEALTHY VOLUNTEERS [J].

Lafuente, A. ;

Gasso, P. ;

Papagianni, K. ;

Mas, S. ;

Fernandez de Bobadilla, R. ;

Arnaiz, J. A. ;

Bernardo, M. .

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 :52-52

[49] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors [J].

Gressier, F. ;

Verstuyft, C. ;

Hardy, P. ;

Becquemont, L. ;

Corruble, E. .

JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) :35-42

[50] Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers [J].

Gasso, Patricia ;

Papagianni, Katerina ;

Mas, Sergi ;

Fernandez de Bobadilla, Ramon ;

Albert Arnaiz, Joan ;

Bernardo, Miquel ;

Lafuente, Amalia .

PHARMACOGENOMICS, 2013, 14 (13) :1551-1563

← 1 2 3 4 5 →